bone marrow transplant for mds patients · bone marrow transplant for mds patients lori muffly md...

19
Bone Marrow Transplant for MDS Patients Lori Muffly MD MS Assistant Professor of Medicine Division of Blood and Marrow Transplantation Stanford University

Upload: trinhhanh

Post on 06-Apr-2019

218 views

Category:

Documents


0 download

TRANSCRIPT

BoneMarrowTransplantforMDSPatients

LoriMufflyMDMSAssistantProfessorofMedicine

DivisionofBloodandMarrowTransplantationStanfordUniversity

• BMT:Thebasics

• BMTforMDS:Theevidence

• InnovativeapproachestoBMTforMDS

WhatisBoneMarrow?

WhatisanAllogeneicBMT?• BMT=bonemarrow(orstemcell)transplant

• Allogeneic=fromaDonor– Someone“immunologically”compatible

• Transplant=Replacerecipient(patient’s)bonemarrowwiththedonor’sbonemarrow– ReplaceRBC,platelets,WBC

HowDoWePerformAllogeneicBMT?

• Medicaltransplant=NOSURGERY

• Howdowecollectdonorstemcells?– BonemarrowharvestinOR– Usestemcellboosterandcollectviaperipheralveins

STEP1:Conditioning/Prep:PreparesBodyto

AcceptDonorStemCells

STEP2:Infusionof

DonorStemCells

STEP3:StemCells“Engraft”

STEP4:Preventsideeffects&re-evaluatemarrowtoensureNOMDS

7-14daysAnhour14-21daysManymonths

WhyDoWePerformAllogeneicBMT?

• Transplant=Replacerecipient(patient’s)bonemarrowwiththedonor’sbonemarrow– ReplaceRBC,platelets,WBC

• New(donor)immunesystemcanbeverypowerfulatcontrollingbloodcancercellsCUREMDS

NewImmuneSystem

NumberofallogeneicBMTs/yr inUShasdoubledinrecentyears

TrendsinAllogeneicBMTUtilizationforAdults≥70Years,byDisease

AbsoluteNo.HCTs≥

70Years

0

20

40

60

80

100

120

140

160

AML MDS/MPS Non-Hodgkinlymphoma Others

MufflyetalBlood2017

• Historically,patients65andolderwithMedicaredidnothavecoverageforBMTforMDS.

• OnAugust4th 2010,theCentersforMedicareandMedicaidservices(CMS)establishedcoverageforBMTforMDSthroughcoveragewithevidencedevelopment(CED).

• ACenterforInternationalBoneMarrowTransplantResearch(CIBMTR)studycomparingoutcomesofpatients55-64vs.65andolderwasapprovedinDecember2010.

WhyisAllogeneicBMTforMDSontheRise?

Atallah etalBlood2017

• Thestudycomparedtheoutcomesof:– 688patientsaged65andolderand– 592patientsaged55-64– whounderwentallogeneicBMTforMDSfrom2010-2014

• Survivalat100daysandattwoyearsfollowingBMTforMDSpatientsaged65andolderiscomparabletopatientsaged55to64.

• AgealoneshouldnotbeadeterminantwhenconsideringBMTforpatientswithMDS.

MedicareCoveragewithEvidenceDevelopmentMDSBMTStudy

Atallah etalBlood2017

HowDoWeDetermineWhichMDSPatienttoTransplant?

DeWitteetalBlood2017

HowDoWeDetermineWhichMDSPatienttoTransplant?

DeWitteetalBlood2017

WhatAreOutcomesafterBMTforMDS?

• Ingeneral….

– 30-40%ofintermediate/highriskMDSpatientswillbecuredfollowingallogeneicBMT

BUT– Somepatientswillhaveseriousmorbidity/mortalityfromthetransplantprocessandsomepatientswillhaverecurrenceofprogressionofMDSafterBMT

HowCanWeImproveAllogeneicBMTforMDS?

STEP1:Conditioning/Prep:PreparesBodyto

AcceptDonorStemCells

STEP2:Infusionof

DonorStemCells

STEP3:StemCells“Engraft”

STEP4:Preventsideeffects&re-evaluatemarrowtoensureNOMDS

AlterthepreptotargetMDScells

Engineeroroptimizedonor

stemcells

1)ReducetoxicityofallogeneicBMT2)AdditionalMDStargetingpost-

BMT

PhaseI/IIClinicalTrialofanMDSStemCellTargetingAntibodyPlusLowIntensityConditioningfor

PatientswithMDSundergoingAllogeneicBMT

ReducingBMTComplications

• PhaseIIIclinicaltrialconductedacrosstheUSaimingtoimprovepost-BMToutcomesforpatientswithMDSandacuteleukemiabyreducingtransplanttoxicity.

Conclusions

• AllogeneicBMTisanimmunotherapythatoffersapotentialforcureforintermediate/highriskMDSpatients

• TheuseofallogeneicBMTforMDS(andforolderadults)isrising

• NewandinnovativeapproachestoBMTareneededtofurtherimproveoutcomes